Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $240.07, for a total transaction of $5,105,568.69. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96.
Beigene Trading Up 4.6 %
NASDAQ ONC opened at $255.37 on Friday. The company has a market capitalization of $24.99 billion, a price-to-earnings ratio of -30.99, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63. Beigene, Ltd. has a fifty-two week low of $126.97 and a fifty-two week high of $260.98. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.
Beigene Company Profile
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
See Also
- Five stocks we like better than Beigene
- Why Are Stock Sectors Important to Successful Investing?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is Insider Trading? What You Can Learn from Insider Trading
- DuPont’s Electronics Spinoff: The Start of Something Big
- About the Markup Calculator
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
